Clinical Trial Update: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating investigational agents as monotherapy or in combination with pembrolizumab for second-line treatment of extensive-stage sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: RECRUITING